MICROCAPS
DEAD

Serial Number

79384325

Owner

ADARE PHARMACEUTICALS S.R.L.

Attorney

Robert S. Broder

Filing Date

Jun 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MICROCAPS Trademark

Serial Number: 79384325

MICROCAPS is a trademark filed by ADARE PHARMACEUTICALS S.R.L. on June 21, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ADARE PHARMACEUTICALS S.R.L. (11 trademarks)

VIA MARTIN LUTHER KING, 13
MILAN 20042 , IT

Entity Type: 16

Trademark Details

Filing Date

June 21, 2023

Registration Date

Not Registered

Goods & Services

Manufacturing services to the order and specification of others of drug dosage forms, drug compositions, drug formulations, drug delivery agents in the nature of tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines, injectables, aerosols, and sanitary products, all in the pharmaceutical and the veterinary fields; clinical manufacturing of drug compositions for others to support clinical trials

Research and development services in the pharmaceutical and the veterinary fields; product design and development of pharmaceutical preparations including powder and granules for suspension in liquids, semisolid forms, solid forms, capsules, tablets, sachets, sprinkles; research and development in the area of drug delivery systems with customized release, taste masked release, controlled release; technological consultancy services in the field of new product development

Pharmaceutical, veterinary and sanitary products, namely, drug delivery agents in the form of specialized tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, filled capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines and injectables used for the treatment of disorders or diseases in the gastrointestinal tract, in the digestive system, in the gut, in the immune systems, in the cardiovascular system, in the respiratory tract, in the blood, in the metabolism, in the nervous system, in the cognition, in the behavior, and in the reproductive tract, gastrointestinal infections, diarrhea, irritable bowel syndrome, inflammatory bowel syndrome disease, enterocolitis, enteritis, ulcerative colitis, cardiovascular disorders, hypertension, thrombosis, vasoconstriction, asthma, inflammation of respiratory tract, bronchoconstriction, thrombocythemia, hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, blood anemia, hypocalcemia, diabetes, diabetic peripheral neuropathy, dyskinesia, hyperkinetic movements, enzyme deficiency, pancreatitis, pancreatectomy, steatorrhea, cystic fibrosis, Paget's disease, bacterial infections, viral infections, fungal infections, osteoporosis, cancer, mucosal and systemic inflammation, functional disease, abdominal pain, allergy, obesity, muscle spasticity, spasms, convulsion, dysthymia, schizophrenia, degenerative dementia, Alzheimer's, stress, anxiety, depression, mood disturbance, sociability disturbance, sleep disturbance, psychological disturbance, attention deficit hyperactivity disorder, addiction, fibromyalgia, obsessive-compulsive disorders, pain, peripheral neuropathic pain, post-surgical pain, back-pain, osteoarthritis; inhalers for medical purposes sold filled with pharmaceutical, veterinary and sanitary preparations for treating asthma, pulmonary hypertension, inflammation of respiratory tract, bronchoconstriction, plasmodium infections and fungal infections

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 30, 2025 DENA
DEATH OF INTERNATIONAL REGISTRATION
Nov 30, 2025 DETH
EXPARTE APPEAL TERMINATED
Oct 23, 2025 EXPT
ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Oct 23, 2025 MAB1
ABANDONMENT - EXPRESS MAILED
Oct 23, 2025 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Oct 22, 2025 EXAR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 17, 2025 OPNX
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 12, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 12, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 12, 2025 CNRT
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 29, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 29, 2025 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 28, 2025 CRFA
ASSIGNED TO LIE
Apr 25, 2025 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 8, 2025 ERFR
EX PARTE APPEAL-INSTITUTED
Apr 8, 2025 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Apr 8, 2025 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Apr 8, 2025 EXAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 5, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 5, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 5, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 5, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 5, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 5, 2024 COAR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 8, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 8, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 8, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 24, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 24, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 2, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 2, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 15, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 14, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 9, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 5, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 1, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 30, 2023 REPR